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Family, twin and epidemiologic studies all point to an important genetic contribution to the risk to develop mood
and anxiety disorders. While some progress has been made in identifying relevant pathomechanisms for these
disorders, candidate based strategies have often yielded controversial findings. Hopes were thus high when
genome-wide genetic association studies became available and affordable and allowed a hypothesis-free approach
to study genetic risk factors for these disorders. In an unprecendented scientific collaborative effort, large
international consortia formed to allow the analysis of these genome-wide association datasets across thousands of
cases and controls ([1] and see also http://www.broadinstitute.org/mpg/ricopili/). Now that large meta-analyses of
genome-wide association studies (GWAS) have been published for bipolar disorder and major depression it has
become clear that main effects of common variants are difficult to identify in these disorders, suggesting that
additional approaches maybe needed to understand the genetic basis of these disorders [2,3].Several factors need to be considered when evaluating
the results of genetic association studies in mood and
anxiety disorders.Phenotype definition
In contrast to other medical disorders, diagnoses for psychi-
atric disorders are still mostly based on verbal report and
observation and not biological measures. It is thus very
likely that our symptom-based diagnoses include patients
with different primary pathophysiological disturbances and
thus likely predisposing genetic variants reducing the power
of genetic association studies. In addition, our diagnostic
scheme may separate individuals with common genetic risk
factors into different categories. For example, it is likely that
bipolar disorder patients share genetic susceptibility loci
with patients with major depression as well as schizophre-
nia [4]. Specific symptom categories are shared across
mood and anxiety disorders and the use of observational di-
mensional behavioural phenotypes that cut across diagnos-
tic categories such as psychotic or anxiety symptoms may
allow to identify new risk genes for psychiatric disorders
[5]. In addition, intermediate phenotype or endophenotypes
in mood and anxiety disorders may be a promisingCorrespondence: ebinder@emory.edu
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reproduction in any medium, provided the orapproach, as it is likely that the effect sizes for genetic asso-
ciations with biological measures are greater than with
more remote psychiatric diagnoses. Such phenotypes in-
clude but are not limited to neuroimaging, endocrine and
neurophysiological measures [6]. In the future, these phe-
notypes could even include in vitro observations on neu-
rons derived from inducible pluripotent stem cells from
patient fibroblasts [7].
Functional annotation of associated variants
The published GWAS in mood disorders all highlight
that a high number of common variants with small odd
ratios likely cumulatively contribute to the risk to suffer
from these disorders [8]. While this implies that very
large samples will be needed to robustly detect these
variants, it also indicates that true associations may not
reach genome-wide significance [9]. This has spurred a
number of re-analyses of GWAS for psychiatric disor-
ders that explore whether functionally relevant genetic
variants maybe be over-represented among the nomin-
ally significant associations and whether this overlap
could highlight specific pathways relevant for the dis-
ease. To date, investigators have mostly focused on using
expression quantitative trait locus (eQTL) analysis as
well as methylation quantitative trait locus (mQTL) ana-
lysis in different tissues to narrow in on putatively func-
tionally relevant polymorphisms, i.e. variants associatedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Binder Biology of Mood & Anxiety Disorders 2012, 2:17 Page 2 of 3
http://www.biolmoodanxietydisord.com/content/2/1/17with different gene expression or DNA methylation
levels [10].
In addition, combining genome-wide protein and gene
expression datasets and studies in animal models of mood
and anxiety disorders with human genetic studies may also
help to identify relevant candidate genes from GWAS. For
example, combining GWAS and gene expression studies
for bipolar disorder, association signals appear to cluster
in discrete regions of the protein–protein interaction net-
work, showing replicated evidence for association for net-
works involving several interlinked signaling pathways,
such as transmission of nerve impulse, Wnt and Notch
signaling [11]. Such analyses highlight the importance of
investigating such datasets not only on the single gene
level but also on the level of functional pathways and new
tools allow for stringent testing of the enrichment of sig-
nals in specific pathways [12]. Such pathway based ana-
lyses also allow better to integrate data from a number of
different sources, such as gene expression and proteome
datasets, GWAS, copy number variation or rare variant
analyses that can highlight overlapping signals from differ-
ent types of studies [13].Common vs. rare variants
For schizophrenia and autism but also bipolar disorder it
has become increasingly clear that rare variants in
addition to common variants contribute to the risk of
disease [14]. New technological developments, including
next generation sequencing will allow us to study large
numbers of patients for the presence of rare functional
variants and data from re-sequencing effort of the
complete RNA coding sequence (exome) are starting to
be published [15]. However, these studies indicate that
very large samples, with over 10,000 individuals will be
required for sufficient power [16].Gene x environment interactions
Finally, the environmental risk component is strong in
mood and anxiety disorders, especially major depression.
A number of candidate gene studies suggest that genes
might moderate the effects of environmental risk factors
in the absence of main genetic effects [17]. GWAS may
profit from the inclusion of environmental exposure as a
variable and this could unmask a number of important
genetic moderator factors that are not apparent when
combining cases and control with different exposure
levels to risk environments. However, genome-wide gene
x environment studies will require larger sample sizes
and will have to deal with the problem of reliably quanti-
fying environmental exposure in studies recruiting from
different populations, especially when using retrospect-
ive measures. Here, the use of epigenetic investigationsin peripheral blood cells may prove useful as biomarker
for environmental exposure [18].Conclusion
In conclusion, while the results from genetic studies in
mood and anxiety disorders may seem disappointing at
first sight, a panoply of new analytic strategies and mo-
lecular genetic tools is likely to yield significant discover-
ies in the near future that further our understanding of
the pathophysiology of these disorders, some of which
will be highlighted in this series.
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